THE IMPACT OF NEW TARGETING METHODS IN THE CANCER THERAPY
Rapid development has achieved in treating tumor to stop malignant cell growth and metastasis in the past decade. Numerous researches have emerged to increase potency and efficacy with novel methods for drug delivery. The main objective of this literature review was to illustrate the impact of current new targeting methods to other previous delivering systems to select the most appropriate method in cancer therapy. This review first gave a brief summary of cancer structure and highlighted the main roles of targeting systems. Different types of delivering systems have been addressed in this literature review with focusing on the latest carrier derived from malarial protein. The remarkable advantages and main limitations of the later have been also discussed. PubMed and Science Direct were the main search engines that have been used as information sources to prepare this review. Articles related to cancer targeting system, active and passive processes, current nanoparticles, antibody carriers, and current novel cancer carriers were used as sources in this review. Important points from many references published in the last decade (2008-2018) were selected and included. Several targeting methods were introduced to enhance the efficacy and tolerability of the toxic drug by active and passive processes, but there is still no conclusive carrier without certain drawbacks. A combination of targeting methods probably shows the most appropriate choice for increasing selectivity and safety of anticancer drugs via reducing the concentration of carriers used.
2. Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomed 2018;13:3921-35.
3. Salanti A, Clausen TM, Agerbaek MO, Al Nakouzi N, Dahlback M, Oo HZ, et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell 2015;28:500-14.
4. Rang HP, Ritter J, Flower RJ, Henderson G. Rang, and dale's pharmacology. Edinburgh: Elsevier Churchill Livingstone; 2016.
5. Hassanpour SH, Dehghani M. Review of cancer from the perspective of molecular. J Cancer Res Practice 2017;4:127-9.
6. Ke X, Shen L. Molecular targeted therapy of cancer: the progress and future prospect. Frontiers Lab Med 2017;1:69-75.
7. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol: Semin Orig Invest 2008;26:57-64.
8. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Delivery Rev 2008;60:1615-26.
9. Li L, Di X, Wu M, Sun Z, Zhong L, Wang Y, et al. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy. Nanomedicine 2017;13:987-98.
10. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs 2005;8:77-84.
11. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Controlled Release 2010;148:135-46.
12. Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK. Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discovery Today 2017;22:1547-56.
13. Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomed: Nanotechnol Biol Med 2018; 14:1407-16.
14. Lei T, Manchanda R, Fernandez-Fernandez A, Huang YC, Wright D, McGoron AJ. Thermal and pH sensitive multifunctional polymer nanoparticles for cancer imaging and therapy. Res Adv 2014;4:17959-68.
15. Koning GA, Eggermont AMM, Lindner LH, Ten Hagen TLM. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res 2010;27:1750-4.
16. Dicheva BM, Koning GA. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors. Expert Opin Drug Delivery 2014;11:83-100.
17. Sawant RR, Torchilin VP. Liposomes as 'smart' pharmaceutical nanocarriers. Soft Matter 2010;6:4026-44.
18. Misra RDK. Magnetic nanoparticle carrier for targeted drug delivery: perspective, outlook, and design. Mater Sci Technol 2008;24:1011-9.
19. Bi H, Han X. Magnetic field triggered drug release from lipid microcapsule containing lipid-coated magnetic nanoparticles. Chem Phys Lett 2018;706:455-60.
20. Hoop M, Ribeiro AS, Rösch D, Weinand P, Mendes N, Mushtaq F, et al. Mobile magnetic nanocatalysts for bioorthogonal targeted cancer therapy. Adv Funct Mater 2018;28:7354-61.
21. Kadam VB, Dhanawade KB, Salunkhe VA, Ubale ATAT. Nanoparticle-novel drug delivery system. Curr Pharma Res 2014;4:1318-35.
22. Kadian R. Nanoparticles: a promising drug delivery approach. Asian J Pharm Clin Res 2018;11:30-5.
23. Pawar HR, Bhosale SS, Derle ND. Use of liposomes in cancer therapy: a review. Int J Pharm Sci Res 2012;3:3585-90.
24. Aravinthrajkumar G, Gayathri R, Vishnupriya V. Targeting the target using nanoparticles-a review. Asian J Pharm Clin Res 2017;10:6-10.
25. Zununi Vahed S, Salehi R, Davaran S, Sharifi S. Liposome-based drug co-delivery systems in cancer cells. Mater Sci Eng C 2017;71:1327-41.
26. Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Controlled Release 2018;277:1-13.
27. Singh RP, Gangadharappa HV, Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. J Drug Delivery Sci Technol 2017;39:166-79.
28. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci 2015;10:81-98.
29. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592-9.
30. Dan N, Setua S, Kashyap KV, Khan S, Jaggi M, Yallapu MM, et al. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals 2018;11:32.
31. Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol 2011;32:510-6.
32. Polakis P. Antibody-drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3-19.
33. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37.
34. Jerjian TV, Glode AE, Thompson LA, O'Bryant CL. Antibody-drug conjugates: a clinical pharmacy perspective on emerging cancer therapy. Pharmacotherapy 2016;36:99-116.
35. Goli N, Bolla PK, Talla V. Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers-an overview. J Drug Delivery Sci Technol 2018;48:106-17.
36. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 2012;29:2354-66.
37. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008;9:423-30.
38. Kim EG, Kim KM. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol Ther 2015;23:493-509.
39. US Food and Drug Administration. Pfizer voluntarily withdraws cancer treatment Mylotarg from U. S. Market; 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm216448.htm. [Last accessed on 15 Sep 2018].
40. Baruch DI, Pasloske BL, Singh HB, Bi X, Ma XC, Feldman M, et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995;82:77-87.
41. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate a?adhering plasmodium falciparum involved in pregnancy?associated malaria. Mol Microbiol 2003;49:179-91.
42. Salanti A, Dahlbäck M, Turner L, Nielsen MA, Barfod L, Magistrado P, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004;200:1197-203.
43. Ferretti C, Bruni L, Dangles Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update 2007;13:121-41.
44. Tuyet Anh Dang T, Chinh Pham T, Quoc Anh N, Thu Ha Vu T, Tien Dung N, Duy Tien D, et al. Synthesis of new bioisosteric hemiasterlin analogues with extremely high cytotoxicity. Bioorg Med Chem Lett 2014;24:5216-8.
45. European Medicines Agency. ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals-questions and answers; 2018. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2018/05/WC500248965.pdf [Last Accessed on 16 Sep 2018].
46. National Institutes of Health. Comparing the Mouse and Human Genomes; 2014. Available from: http://www.nih.gov/news-events/nih-research-matters/comparing-mouse-human-genomes. [Last Accessed on 16 Sep 2018]
47. Goodall S, Jones ML, Mahler S. Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy-future prospects. J Chem Technol Biotechnol 2015;90:1169-76.
48. Alibakhshi A, Abarghooi Kahaki F, Ahangarzadeh S, Yaghoobi H, Yarian F, Arezumand R, et al. Targeted cancer therapy through antibody fragments-decorated nanomedicines. J Controlled Release 2017;268:323-34.
49. Son S, Shin S, Rao NV, Um W, Jeon J, Ko H, et al. Anti-trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int J Biol Macromol 2018;110:406-15.
50. Zhang Y, Guo J, Zhang XL, Li DP, Zhang TT, Gao FF, et al. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. Int J Pharm 2015;496:1026-33.